

Kidney transplantation, rejection prophylaxis

Adults:

→ *Oral*: 9 ± 3 mg/kg/day in 2 divided doses

Target Cyclosporine Blood Concentrations in Adult Kidney Transplant Recipients ^[1]:


Time Post Transplant (Months)	Cyclosporine Trough Concentration (ng/mL) Tandem Mass Spectrometry Assay	Cyclosporine C2 Concentration (ng/mL) Tandem Mass Spectrometry Assay
ADULT Kidney and Kidney Pancreas Transplant Recipients (Oct 2014)		
Less than 1 months	300 to 350	1300
1 to 2 months	250 to 300	1100
3 to 6 months	150 to 250	800 to 900
7 to 12 months	125 to 200	700
Greater than 12 months	75 to 125	450-600

Pediatrics:

→ *Oral*: initial dose: 9 ± 3 mg/ kg/day in 2 divided doses

Target Cyclosporine Blood Concentrations in Pediatric Kidney Transplant Recipients ^[1]:

Time Post Transplant (Months)	Cyclosporine Trough Concentration (ng/mL) Tandem Mass Spectrometry Assay	Cyclosporine C2 Concentration (ng/mL) Tandem Mass Spectrometry Assay
PEDIATRIC Kidney Transplant* Recipients (Oct 2014)		
Less than 1 months	200 to 250	Not used
1 to 2 months	150 to 200	Not used
2 to 3 months	100 to 150	Not used
Greater than 3 months	80 to 100	Not used



[1] - BC Transplant. (2021, May 13). MEDICATION GUIDELINES FOR SOLID ORGAN TRANSPLANTS. BC Transplant.

(<http://www.transplant.bc.ca/Documents/Health%20Professionals/Clinical%20guidelines/Clinical%20Guidelines%20for%20Transplant%20Medications.pdf>)

